05.05.2021
Commenting on the announcement, Dong Ki Lee, CEO of OliX Pharmaceuticals said:
"We are very excited to collaborate with PCI Biotech. Combining our proprietary
asiRNA platform with PCI's leading fimaNAc delivery technology will
significantly accelerate our efforts to bring our dermatological RNAi programs
to the clinic. We also expect to expand the area of application to our cancer
immunotherapy pipeline and mRNA vaccines developed by our subsidiary, mCureX, in

PCI Biotech's CEO, Per Walday, added: "We are very pleased to initiate this
exciting collaboration with OliX Pharmaceuticals. This collaboration builds on
the strong potential of our intracellular delivery platform technology for
nucleic acid based therapies, within a therapeutic field of good technological
fit. Combining the leading technologies of OliX Pharmaceuticals and PCI Biotech
may lead to new promising applications and we look forward to the
collaboration."
the near future."

30 apr.PCI Biotech: First US patient enrolled in the fimaChem pivotal RELEASE studyPCIBLes hele artikkelen
Oslo (Norway), 30 April 2021 PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced that the first US patient has been enrolled into the fimaChem pivotal RELEASE study with registration intent in inoperable bile duct cancer patients. The RELEASE study spans across Europe, USA and Asia, with patient enrolment initiated in all continents.


Per Walday, CEO, said: It is reassuring to see screening activity and enrolment picking up across the geographies of the RELEASE study, despite Covid-19 still having an impact on the healthcare systems. We are focused on optimal execution of the RELEASE study, to bring a new treatment option to a patient group with a high unmet medical need.

Contact information:

Per Walday, CEO

pw@pcibiotech.no

Mobile: +47 917 93 429

About the RELEASE study

The pivotal RELEASE study design is based on the outcome of meetings with the two leading regulatory authorities European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). The study programme consists of a single open randomised two-arm study with 186 patients (93 patients per arm), having a control arm with the standard of care (SoC) treatment of up to eight cycles of the chemotherapies gemcitabine and cisplatin, and an experimental arm with up to two fimaChem treatments in addition to SoC. The studys primary endpoint is progression free survival (PFS), with overall survival (OS) as a key secondary endpoint. The study includes an interim analysis of objective response rate (ORR), with the potential of accelerated/conditional marketing approval. In addition, the study contains several other secondary endpoints that provide the opportunity to generate robust comparative data of importance for market acceptance of fimaChem as a first-line treatment for inoperable bile duct cancer. The study is done at clinical sites across Europe, USA and Asia.

About PCI Biotech

PCI Biotech is a biopharmaceutical late stage clinical development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The companys lead programme fimaChem consists of a pivotal study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.

For further information, please visit: www.pcibiotech.com

Forward-looking statements

This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.